Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 76

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 76
---
 LNP 
 adoption in mRNA vaccine development [7].                                                 |

The demonstrated success of LNPs in COVID-19
vaccines has fueled expanded research into their application in gene therapy, oncology, and other infectious diseases [8].

Our proprietary technology builds on the same
principles that made Doxil®, the first FDA-approved Nanomedicine using liposomal drug delivery, a success. We apply these principles
to treat infectious diseases and cancer by encapsulating potent therapeutics in novel lipid-based particles. By encapsulating potent
therapeutics within novel lipid-based particles, we achieve controlled drug release, targeted delivery, and extended circulation time,
ultimately leading to greater efficacy and fewer systemic side effects.

References

| 1. | De Villiers MM, Aramwit P, Kwon GS. Nanotechnology in Drug Delivery. 
 Springer, 2008.                                                      |

| 2. | Allen TM, Cullis PR. Liposomal drug delivery systems: From concept 
 to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.    |

| 3. | He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution and                                 
 urinary excretion of mesoporous silica nanoparticles: Effects of particle size and PEGylation. 
 Small. 2011;7(2):271–280.                                                                      |

| 4. | Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances             
 and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. |

| 5. | EMA Assessment Report – Comirnaty (BioNTech/Pfizer). EMA/707383/2020. |

| 6. | Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of    
 the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. |

| 7. | Arcturus Therapeutics Press Releases, 2020–2021. |

| 8. | Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA 
 delivery. Nat Rev Mater. 2021;6:1078–1094.                    |

<div align='center'>45

Product Pipeline in Development</div>